S&P 500   4,304.97 (+0.26%)
DOW   33,894.04 (+0.18%)
QQQ   355.80 (+0.75%)
AAPL   182.14 (+0.87%)
MSFT   328.46 (+0.98%)
META   265.35 (+0.29%)
GOOGL   123.02 (+0.72%)
AMZN   124.48 (+0.19%)
TSLA   247.21 (+5.26%)
NVDA   391.41 (+1.64%)
NIO   7.82 (+0.39%)
BABA   85.91 (-0.27%)
AMD   125.64 (+3.79%)
T   16.02 (-0.31%)
F   13.80 (+1.62%)
MU   65.59 (+0.41%)
CGC   0.67 (-4.02%)
GE   106.01 (-0.06%)
DIS   91.97 (-0.61%)
AMC   4.75 (+1.50%)
PFE   38.94 (-0.38%)
PYPL   63.75 (-0.76%)
NFLX   423.29 (+3.40%)
S&P 500   4,304.97 (+0.26%)
DOW   33,894.04 (+0.18%)
QQQ   355.80 (+0.75%)
AAPL   182.14 (+0.87%)
MSFT   328.46 (+0.98%)
META   265.35 (+0.29%)
GOOGL   123.02 (+0.72%)
AMZN   124.48 (+0.19%)
TSLA   247.21 (+5.26%)
NVDA   391.41 (+1.64%)
NIO   7.82 (+0.39%)
BABA   85.91 (-0.27%)
AMD   125.64 (+3.79%)
T   16.02 (-0.31%)
F   13.80 (+1.62%)
MU   65.59 (+0.41%)
CGC   0.67 (-4.02%)
GE   106.01 (-0.06%)
DIS   91.97 (-0.61%)
AMC   4.75 (+1.50%)
PFE   38.94 (-0.38%)
PYPL   63.75 (-0.76%)
NFLX   423.29 (+3.40%)
S&P 500   4,304.97 (+0.26%)
DOW   33,894.04 (+0.18%)
QQQ   355.80 (+0.75%)
AAPL   182.14 (+0.87%)
MSFT   328.46 (+0.98%)
META   265.35 (+0.29%)
GOOGL   123.02 (+0.72%)
AMZN   124.48 (+0.19%)
TSLA   247.21 (+5.26%)
NVDA   391.41 (+1.64%)
NIO   7.82 (+0.39%)
BABA   85.91 (-0.27%)
AMD   125.64 (+3.79%)
T   16.02 (-0.31%)
F   13.80 (+1.62%)
MU   65.59 (+0.41%)
CGC   0.67 (-4.02%)
GE   106.01 (-0.06%)
DIS   91.97 (-0.61%)
AMC   4.75 (+1.50%)
PFE   38.94 (-0.38%)
PYPL   63.75 (-0.76%)
NFLX   423.29 (+3.40%)
S&P 500   4,304.97 (+0.26%)
DOW   33,894.04 (+0.18%)
QQQ   355.80 (+0.75%)
AAPL   182.14 (+0.87%)
MSFT   328.46 (+0.98%)
META   265.35 (+0.29%)
GOOGL   123.02 (+0.72%)
AMZN   124.48 (+0.19%)
TSLA   247.21 (+5.26%)
NVDA   391.41 (+1.64%)
NIO   7.82 (+0.39%)
BABA   85.91 (-0.27%)
AMD   125.64 (+3.79%)
T   16.02 (-0.31%)
F   13.80 (+1.62%)
MU   65.59 (+0.41%)
CGC   0.67 (-4.02%)
GE   106.01 (-0.06%)
DIS   91.97 (-0.61%)
AMC   4.75 (+1.50%)
PFE   38.94 (-0.38%)
PYPL   63.75 (-0.76%)
NFLX   423.29 (+3.40%)

Bicycle Therapeutics (BCYC) Stock Forecast, Price & News

$25.86
+0.77 (+3.07%)
(As of 02:16 PM ET)
Compare
Today's Range
$25.00
$25.90
50-Day Range
$18.95
$25.98
52-Week Range
$12.08
$33.49
Volume
29,397 shs
Average Volume
283,195 shs
Market Capitalization
$776.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.20

Bicycle Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
106.3% Upside
$53.20 Price Target
Short Interest
Bearish
14.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.36mentions of Bicycle Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$55,477 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.91) to ($5.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

776th out of 986 stocks

Pharmaceutical Preparations Industry

375th out of 480 stocks


BCYC stock logo

About Bicycle Therapeutics (NASDAQ:BCYC) Stock

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Stock News Headlines

This Stock's Worth Researching
Uncover the buzz behind this trending stock. Read the comprehensive report here.
This Stock's Worth Researching
Uncover the buzz behind this trending stock. Read the comprehensive report here.
8-K: BICYCLE THERAPEUTICS plc
14 Analysts Have This to Say About Bicycle Therapeutics
Bayer inks $1.7B deal with Bicycle Therapeutics
See More Headlines

BCYC Price History

BCYC Company Calendar

Last Earnings
11/03/2021
Today
6/09/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCYC
Fax
N/A
Employees
119
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$53.20
High Stock Price Forecast
$74.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+112.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

Net Income
$-112,720,000.00
Net Margins
-801.45%
Pretax Margin
-812.57%

Debt

Sales & Book Value

Annual Sales
$14.46 million
Book Value
$9.12 per share

Miscellaneous

Free Float
26,979,000
Market Cap
$753.70 million
Optionable
Not Optionable
Beta
0.74

Key Executives

  • Kevin LeeKevin Lee
    Chief Executive Officer & Executive Director
  • Lee H. KalowskiLee H. Kalowski
    President & Chief Financial Officer
  • Alistair Milnes
    Chief Operating Officer
  • Michael Skynner
    Chief Technology Officer
  • Nicholas KeenNicholas Keen
    Chief Scientific Officer













BCYC Stock - Frequently Asked Questions

Should I buy or sell Bicycle Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BCYC shares.
View BCYC analyst ratings
or view top-rated stocks.

What is Bicycle Therapeutics' stock price forecast for 2023?

11 brokerages have issued 12-month price objectives for Bicycle Therapeutics' shares. Their BCYC share price forecasts range from $30.00 to $74.00. On average, they expect the company's stock price to reach $53.20 in the next twelve months. This suggests a possible upside of 112.0% from the stock's current price.
View analysts price targets for BCYC
or view top-rated stocks among Wall Street analysts.

How have BCYC shares performed in 2023?

Bicycle Therapeutics' stock was trading at $29.60 at the beginning of 2023. Since then, BCYC shares have decreased by 15.2% and is now trading at $25.09.
View the best growth stocks for 2023 here
.

When is Bicycle Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our BCYC earnings forecast
.

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) issued its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.02. The company had revenue of $4.33 million for the quarter, compared to analysts' expectations of $5.29 million. Bicycle Therapeutics had a negative net margin of 801.45% and a negative trailing twelve-month return on equity of 44.57%.

What other stocks do shareholders of Bicycle Therapeutics own?
When did Bicycle Therapeutics IPO?

(BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Bicycle Therapeutics' stock symbol?

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Who are Bicycle Therapeutics' major shareholders?

Bicycle Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Candriam S.C.A. (6.12%), Sio Capital Management LLC (4.54%), Logos Global Management LP (3.52%), Armistice Capital LLC (3.45%), First Light Asset Management LLC (3.28%) and AXA S.A. (2.16%). Insiders that own company stock include Kate Bingham, Kevin Lee, Lee Kalowski, Michael Skynner, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander.
View institutional ownership trends
.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bicycle Therapeutics' stock price today?

One share of BCYC stock can currently be purchased for approximately $25.09.

How much money does Bicycle Therapeutics make?

Bicycle Therapeutics (NASDAQ:BCYC) has a market capitalization of $753.70 million and generates $14.46 million in revenue each year. The company earns $-112,720,000.00 in net income (profit) each year or ($4.17) on an earnings per share basis.

How many employees does Bicycle Therapeutics have?

The company employs 119 workers across the globe.

How can I contact Bicycle Therapeutics?

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The official website for the company is www.bicycletherapeutics.com. The company can be reached via phone at 441223261503 or via email at david.borah@bicycletx.com.

This page (NASDAQ:BCYC) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -